| - Industry | - Sector | Dr. Terrence W. Norchi M.D. CEO | OTCQB Exchange | US03939W1099 ISIN |
| United States Country | 8 Employees | - Last Dividend | 18 Jan 2023 Last Split | - IPO Date |
Arch Therapeutics, Inc., alongside its subsidiaries, positions itself within the United States as a pioneering entity in the biotechnology sector. The essence of its operations is encapsulated in the development and commercialization of innovative solutions derived from its proprietary AC5 self-assembling technology platform. This platform is heralded for its efficacy in arresting bleeding, managing leaks, and navigating the intricacies of wound care across a spectrum encompassing surgery, trauma, interventional procedures, and conditions borne out of disease. Having planted its roots in 2006, the company commands a strategic base in Framingham, Massachusetts, reflecting a blend of seasoned experience and locality which nurtures innovation.